Skip to main content
Clinical Trials/CTRI/2020/11/029266
CTRI/2020/11/029266Not yet recruiting未知

Assessment of novel inflammatory, clinical and radiologicalresponse (â??Brixiaâ?? chest X ray score) to remdesivir in moderate and severe COVID-19patients : a retrospective study

Vishal Shanbhag0 sites0 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
未知
Status
Not yet recruiting
Sponsor

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Inclusion Criteria

  • •Patients aged 18-90 years were included
  • •Patients who have been proven COVID-19 positive by reverse transcriptase polymerase chain reaction (RT-PCR),and the rapid antigen test.
  • •COVID -19 patients admitted between June 2020 and September 2020
  • •Patients above 18 years admitted to hospital or critical care unit and on oxygen therapy, non-invasive ventilation (NIV) or invasive mechanical ventilation (IMV)

Exclusion Criteria

  • •Patients with pre-existing liver disorders.
  • •2. Patients with any prior hypoalbuminemic state.
  • •3. Patients with hematological malignancies, immunocompromised states.
  • •4. Patients with fluid resuscitations where the serum albumin level couldbe altered.
  • •5. patients with trauma,extensive bowel resection,burns
  • •6. Patients with AKI or CKD with possible albumin loss in urine

Investigators

Sponsor
Vishal Shanbhag

Similar Trials

Response of patients and chest x-ray... | Clinical Trial